Concepts (105)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 6 | 2019 | 131 | 0.420 |
Why?
|
| Liver Neoplasms | 5 | 2018 | 164 | 0.360 |
Why?
|
| Adenocarcinoma | 5 | 2019 | 298 | 0.300 |
Why?
|
| Hepatectomy | 4 | 2018 | 57 | 0.290 |
Why?
|
| Colorectal Neoplasms | 4 | 2018 | 219 | 0.270 |
Why?
|
| Postoperative Complications | 3 | 2017 | 818 | 0.190 |
Why?
|
| Neuroendocrine Tumors | 2 | 2019 | 19 | 0.170 |
Why?
|
| Anesthesia, Conduction | 1 | 2018 | 24 | 0.130 |
Why?
|
| Communication Barriers | 1 | 2017 | 18 | 0.130 |
Why?
|
| Digestive System Neoplasms | 1 | 2017 | 3 | 0.130 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2017 | 23 | 0.120 |
Why?
|
| Laparotomy | 1 | 2017 | 30 | 0.120 |
Why?
|
| Quality Assurance, Health Care | 1 | 2017 | 72 | 0.120 |
Why?
|
| Negative-Pressure Wound Therapy | 1 | 2017 | 38 | 0.120 |
Why?
|
| Risk | 1 | 2017 | 305 | 0.120 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 98 | 0.120 |
Why?
|
| Biliary Tract Neoplasms | 2 | 2004 | 10 | 0.100 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 2238 | 0.090 |
Why?
|
| Vena Cava Filters | 1 | 1991 | 12 | 0.080 |
Why?
|
| Crohn Disease | 1 | 1991 | 31 | 0.080 |
Why?
|
| Survival Rate | 4 | 2018 | 892 | 0.080 |
Why?
|
| Aged | 10 | 2019 | 10249 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2005 | 442 | 0.080 |
Why?
|
| Hemorrhage | 1 | 1991 | 95 | 0.080 |
Why?
|
| Pulmonary Embolism | 1 | 1991 | 51 | 0.080 |
Why?
|
| Humans | 15 | 2019 | 32262 | 0.070 |
Why?
|
| Retrospective Studies | 4 | 2019 | 3609 | 0.070 |
Why?
|
| Male | 10 | 2019 | 19429 | 0.060 |
Why?
|
| Prognosis | 3 | 2019 | 1529 | 0.060 |
Why?
|
| Middle Aged | 8 | 2017 | 11837 | 0.060 |
Why?
|
| Female | 9 | 2019 | 19935 | 0.060 |
Why?
|
| Telomerase | 1 | 2006 | 20 | 0.060 |
Why?
|
| Camptothecin | 2 | 2005 | 45 | 0.060 |
Why?
|
| DNA, Neoplasm | 1 | 2006 | 52 | 0.060 |
Why?
|
| Deoxycytidine | 2 | 2005 | 57 | 0.060 |
Why?
|
| Endosonography | 1 | 2006 | 55 | 0.060 |
Why?
|
| Peritoneal Neoplasms | 1 | 2008 | 256 | 0.060 |
Why?
|
| Treatment Outcome | 4 | 2018 | 3408 | 0.060 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2004 | 7 | 0.050 |
Why?
|
| Cystadenocarcinoma | 1 | 2004 | 3 | 0.050 |
Why?
|
| Oxyphil Cells | 1 | 2004 | 2 | 0.050 |
Why?
|
| Catheter Ablation | 1 | 2004 | 113 | 0.050 |
Why?
|
| Morbidity | 2 | 2017 | 98 | 0.050 |
Why?
|
| Cryosurgery | 1 | 2002 | 25 | 0.050 |
Why?
|
| Aged, 80 and over | 4 | 2017 | 3893 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2017 | 2315 | 0.040 |
Why?
|
| Adult | 6 | 2017 | 9252 | 0.040 |
Why?
|
| Malpractice | 1 | 2017 | 20 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2017 | 99 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2017 | 59 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 242 | 0.030 |
Why?
|
| Young Adult | 2 | 2017 | 2643 | 0.030 |
Why?
|
| Surgical Procedures, Operative | 1 | 2017 | 79 | 0.030 |
Why?
|
| Paraneoplastic Endocrine Syndromes | 1 | 1996 | 1 | 0.030 |
Why?
|
| Communication | 1 | 2017 | 128 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2017 | 179 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2017 | 230 | 0.030 |
Why?
|
| Adolescent | 2 | 2017 | 3509 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2017 | 245 | 0.030 |
Why?
|
| Logistic Models | 1 | 2017 | 743 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2008 | 551 | 0.030 |
Why?
|
| Incidence | 1 | 2017 | 1241 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 1478 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 1839 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2013 | 62 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2013 | 185 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2013 | 476 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 650 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 1423 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 772 | 0.020 |
Why?
|
| Colectomy | 1 | 1991 | 30 | 0.020 |
Why?
|
| Hematoma | 1 | 1991 | 26 | 0.020 |
Why?
|
| Arteries | 1 | 1991 | 75 | 0.020 |
Why?
|
| Risk Factors | 1 | 2017 | 3933 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 595 | 0.020 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2008 | 154 | 0.020 |
Why?
|
| Hyperthermia, Induced | 1 | 2008 | 236 | 0.010 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2006 | 62 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2006 | 186 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 2005 | 30 | 0.010 |
Why?
|
| Vomiting | 1 | 2005 | 20 | 0.010 |
Why?
|
| Nausea | 1 | 2005 | 50 | 0.010 |
Why?
|
| Diarrhea | 1 | 2005 | 56 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2005 | 83 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 2005 | 50 | 0.010 |
Why?
|
| Fatigue | 1 | 2005 | 80 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2005 | 322 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 276 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 556 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 500 | 0.010 |
Why?
|
| Heart Failure | 1 | 1991 | 728 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 2004 | 34 | 0.010 |
Why?
|
| Disease Progression | 1 | 2005 | 591 | 0.010 |
Why?
|
| Gallbladder Neoplasms | 1 | 2002 | 35 | 0.010 |
Why?
|
| Neutropenia | 1 | 2002 | 24 | 0.010 |
Why?
|
| Lymph Node Excision | 1 | 2002 | 94 | 0.010 |
Why?
|
| Mitochondria | 1 | 2004 | 211 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2004 | 461 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2002 | 716 | 0.010 |
Why?
|
| Parathyroid Hormone-Related Protein | 1 | 1996 | 1 | 0.010 |
Why?
|
| Gastrins | 1 | 1996 | 4 | 0.010 |
Why?
|
| Somatostatin | 1 | 1996 | 11 | 0.010 |
Why?
|
| Parathyroid Hormone | 1 | 1996 | 45 | 0.010 |
Why?
|
| Proteins | 1 | 1996 | 149 | 0.010 |
Why?
|
| Insulin | 1 | 1996 | 359 | 0.010 |
Why?
|